CNSY
Cerenome, Inc.
There isn't enough reported data to score CNSY yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CNSY Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
CNSY's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CNSY PE Valuation
CNSY has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CNSY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CNSY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CNSY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$69.50 | +$51.75 |
| Q4 2024 | -$58.50 | +$96.50 |
| Q3 2024 | -$108.50 | +$40.00 |
| Q2 2024 | -$124.25 | +$70.50 |
| Q1 2024 | -$121.25 | +$148.75 |
| Q4 2023 | -$155.00 | +$133.75 |
| Q3 2023 | -$148.50 | +$177.75 |
| Q2 2023 | -$194.75 | +$165.25 |
CNSY has the stronger earnings trend. Trailing diluted EPS is down 157% for CNSY versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CNSY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $411K | -70% |
| Q1 2026 | $1M | -2.9% |
HIMS has the edge over CNSY in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2204% | -2093 points |
| Q1 2026 | -693% | -359 points |
| Q4 2025 | -420% | N/A |
| Q3 2025 | -321% | N/A |
| Q2 2025 | -111% | N/A |
| Q1 2025 | -334% | N/A |
CNSY's operating margin was −2204% last quarter, down 2093 points from the same quarter a year ago, near the bottom of its range since 2025.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CNSY in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CNSY on profitability, with a higher operating margin.
CNSY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | -$1.8M |
| Q1 2026 | -$7.1M | -$881K |
| Q4 2025 | -$6.3M | -$5.1M |
| Q3 2025 | -$2.6M | +$1.1M |
| Q2 2025 | -$5.8M | -$4.6M |
| Q1 2025 | -$6.2M | -$1.6M |
| Q4 2024 | -$1.2M | +$659K |
| Q3 2024 | -$3.7M | -$1.3M |
CNSY has burned cash in almost every quarter: −$24M over the past year, against −$17M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CNSY on cash generation, producing positive trailing cash flow while its opponent burns cash.
CNSY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +89% | +275K shares |
| 1 year | +237% | +410K shares |
| 3 years | +1834% | +553K shares |
CNSY has 582,669 diluted shares, up 237% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $374,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CNSY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CNSY Net Leverage
CNSY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CNSY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.2 | Oversold |
| Stochastic | 6.0 | Oversold |
CNSY's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CNSY PE vs Healthcare Sector
CNSY has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CNSY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.50 | 49% below |
| 20 week MA | $2.61 | 70% below |
| 50 week MA | $5.70 | 86% below |
| 100 week MA | $11.8 | 93% below |
| 200 week MA | $35.8 | 98% below |
CNSY is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CNSY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $922.5 | $836.3 | -9.3% |
| 2021 | $836.3 | $442.5 | -47% |
| 2022 | $442.5 | $116.3 | -74% |
| 2023 | $116.3 | $43.8 | -62% |
| 2024 | $43.8 | $29.0 | -34% |
| 2025 | $29.0 | $14.5 | -50% |
| 2026 YTD | $14.5 | $0.77 | -95% |
CNSY has finished every year since 2020 lower, and it's down 95% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CNSY on returns for 2026, with the stronger performance.